Limits on costs and values of anticancer drugs in metastatic colorectal cancer: Policies and proposal.

被引：0
|
作者：
Guirgis, Helmy M. [1 ]
机构：
[1] Univ Calif Irvine, Orange, CA 92668 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
607
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Utilization profiles and costs of cetuximab in the taking charge of colorectal metastatic cancer
    Ruhmann, A.
    Perrier-Cornet, E.
    Serra, S.
    Palascak, V
    Ben Abdelgheni, M.
    Beretz, L.
    Bergerat, J. P.
    Kurtz, J. E.
    Leveque, D.
    BULLETIN DU CANCER, 2007, 94 (06) : 588 - 588
  • [32] Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer
    Paramore, L. Clark
    Thomas, Sirnu K.
    Knopf, Kevin B.
    Cragin, Lael S.
    Fraeman, Kathy H.
    CLINICAL COLORECTAL CANCER, 2006, 6 (01) : 52 - 58
  • [33] Does survival increase in metastatic breast cancer with recently available anticancer drugs?
    Abrial, C
    Leheurteur, M
    Cabrespine, A
    Mouret-Reynier, MA
    Durando, X
    Ferriere, JP
    Kwiatkowski, F
    Penault-Llorca, F
    Cure, H
    Chollet, P
    ONCOLOGY RESEARCH, 2006, 15 (09) : 431 - 439
  • [34] Enhancing the effect of anticancer drugs against the colorectal cancer cell line with electroporation
    Kambe, M
    Arita, D
    Kikuchi, H
    Funato, T
    Tezuka, F
    Gamo, M
    Murakawa, Y
    Kanamaru, R
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 180 (02): : 161 - 171
  • [35] PES1 regulates sensitivity of colorectal cancer cells to anticancer drugs
    Xie, Wei
    Qu, Like
    Meng, Lin
    Liu, Caiyun
    Wu, Jian
    Shou, Chengchao
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 431 (03) : 460 - 465
  • [36] Engineering of anticancer drugs entrapped polymeric nanoparticles for the treatment of colorectal cancer therapy
    Meng, Fanqi
    Yun, Zhennan
    Yan, Guoqiang
    Wang, Guangyi
    Lin, Chao
    PROCESS BIOCHEMISTRY, 2021, 111 : 36 - 42
  • [37] Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer (mCRC).
    Paramore, L. C.
    Thomas, S.
    Knopf, K. B.
    Cragin, L.
    Fraeman, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 321S - 321S
  • [38] COURSE OF THERAPY, RESOURCE UTILIZATION AND COSTS FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN GERMANY
    Grabe, K.
    Pfeifer, S.
    Osowski, U.
    VALUE IN HEALTH, 2016, 19 (07) : A728 - A728
  • [39] TOTAL HEALTH CARE COSTS FOR COLORECTAL CANCER PATIENTS FOLLOWING METASTATIC DIAGNOSIS
    Chastek, B.
    Kulakodlu, M.
    Valluri, S.
    Seal, B.
    VALUE IN HEALTH, 2012, 15 (04) : A1 - A1
  • [40] Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer: The optimization of pharmacological costs
    Giuliani, J.
    Bonetti, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 62 - 62
12345